Valeant announecs approval of Retin-A Micro microsphere 0.08% Valeant announced that it has received approval from the FDA for its Supplemental New Drug Application for Retin-A Micro Gel microsphere 0.08% for the topical treatment of acne vulgaris.
News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.
Piper Jaffray tech and biopharma analysts hold analyst/industry conference call Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
Drug deals increase to new high, Bloomberg says M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link